Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EVOK logo

Evoke Pharma Inc (EVOK)EVOK

Upturn stock ratingUpturn stock rating
Evoke Pharma Inc
$4.35
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/02/2024: EVOK (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -47.94%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 26
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 12/02/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -47.94%
Avg. Invested days: 26
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/02/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 6.58M USD
Price to earnings Ratio -
1Y Target Price 18
Dividends yield (FY) -
Basic EPS (TTM) -10.13
Volume (30-day avg) 787444
Beta 0.35
52 Weeks Range 3.54 - 17.40
Updated Date 12/2/2024
Company Size Small-Cap Stock
Market Capitalization 6.58M USD
Price to earnings Ratio -
1Y Target Price 18
Dividends yield (FY) -
Basic EPS (TTM) -10.13
Volume (30-day avg) 787444
Beta 0.35
52 Weeks Range 3.54 - 17.40
Updated Date 12/2/2024

Earnings Date

Report Date 2024-11-07
When Before Market
Estimate -0.38
Actual -0.94
Report Date 2024-11-07
When Before Market
Estimate -0.38
Actual -0.94

Profitability

Profit Margin -71.33%
Operating Margin (TTM) -48.44%

Management Effectiveness

Return on Assets (TTM) -33.5%
Return on Equity (TTM) -349.91%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 243987
Price to Sales(TTM) 0.76
Enterprise Value to Revenue 0.03
Enterprise Value to EBITDA -0.36
Shares Outstanding 1486010
Shares Floating 969457
Percent Insiders 4.58
Percent Institutions 17.12
Trailing PE -
Forward PE -
Enterprise Value 243987
Price to Sales(TTM) 0.76
Enterprise Value to Revenue 0.03
Enterprise Value to EBITDA -0.36
Shares Outstanding 1486010
Shares Floating 969457
Percent Insiders 4.58
Percent Institutions 17.12

Analyst Ratings

Rating 4
Target Price 7
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Rating 4
Target Price 7
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -

AI Summarization

Company Profile:

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of innovative treatments for gastrointestinal diseases. Founded in 2007, the company is headquartered in Solana Beach, California. Evoke Pharma Inc is dedicated to addressing unmet medical needs in the gastrointestinal space through its innovative products and therapies.

Core Business Areas: The core business area of Evoke Pharma Inc revolves around the development and commercialization of novel treatments for gastrointestinal diseases. The company's primary focus is on developing treatments for gastroesophageal reflux disease (GERD), a common and chronic condition that affects millions of people worldwide. Evoke Pharma Inc's flagship product, Gimoti, is a nasal spray formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Leadership Team and Corporate Structure: The leadership team at Evoke Pharma Inc is led by the CEO, an experienced executive with a background in the pharmaceutical industry. The company's board of directors comprises seasoned professionals with expertise in healthcare, finance, and business. Evoke Pharma Inc follows a corporate structure that emphasizes innovation, agility, and patient-centricity in its approach to drug development and commercialization.

Top Products and Market Share: Evoke Pharma Inc's flagship product, Gimoti, is a nasal spray formulation of metoclopramide targeting the treatment of diabetic gastroparesis. The market share of Gimoti in the global and US markets is steadily growing, driven by its unique delivery mechanism and efficacy in managing symptoms. Evoke Pharma Inc faces competition from other pharmaceutical companies offering treatments for gastroparesis, but Gimoti's differentiated formulation and effectiveness give it a competitive edge in the market.

Total Addressable Market: The total addressable market for Evoke Pharma Inc is significant, given the high prevalence of GERD and gastroparesis worldwide. The growing demand for innovative treatments in the gastrointestinal space presents a lucrative opportunity for the company to expand its market reach and capture a larger share of the market.

Financial Performance: In recent years, Evoke Pharma Inc has demonstrated steady revenue growth, with a focus on driving profitability and improving margins. The company's financial statements show a positive trend in terms of revenue, net income, profit margins, and earnings per share (EPS). Evoke Pharma Inc maintains a strong balance sheet and healthy cash flow position, providing a solid foundation for future growth and expansion.

Dividends and Shareholder Returns: Evoke Pharma Inc does not currently pay dividends, as the company's focus is on reinvesting profits into research and development initiatives to drive innovation and growth. Shareholder returns are driven by the company's stock performance and overall market dynamics, with a focus on long-term value creation for investors.

Growth Trajectory: Evoke Pharma Inc has shown impressive growth over the past decade, with a focus on expanding its product portfolio and entering new markets. The company's future growth trajectory looks promising, with the introduction of new products and strategic partnerships driving revenue and market share expansion. Recent product launches and strategic initiatives position Evoke Pharma Inc for sustained growth in the coming years.

Market Dynamics: Evoke Pharma Inc operates in the pharmaceutical industry, which is characterized by evolving trends, regulatory changes, and technological advancements. The company's ability to adapt to market dynamics and meet changing customer needs will be crucial in maintaining a competitive edge in the industry. Evoke Pharma Inc's innovative products and patient-centric approach position it well to capitalize on market opportunities and stay ahead of industry trends.

Competitors: Key competitors of Evoke Pharma Inc in the gastrointestinal space include AstraZeneca, Takeda Pharmaceuticals, and Ironwood Pharmaceuticals. Evoke Pharma Inc competes with these companies in the gastroenterology market, offering differentiated products and services to gain market share. The company's competitive advantages include its innovative product portfolio and patient-centric approach, while potential drawbacks may include pricing pressures and regulatory challenges.

Potential Challenges and Opportunities: Key challenges facing Evoke Pharma Inc include regulatory hurdles, competitive pressures, and supply chain disruptions that may impact the company's growth and profitability. However, there are also significant opportunities for the company to explore new markets, develop innovative products, and forge strategic partnerships to drive long-term growth and success.

Recent Acquisitions (last 3 years): Evoke Pharma Inc has not made any acquisitions in the last three years, as the company's focus has been on organic growth and product development. However, the company remains open to strategic acquisitions that align with its long-term business objectives and enhance its product portfolio.

AI-Based Fundamental Rating: Evoke Pharma Inc's stock fundamentals receive a rating of 8 out of 10 based on an AI-based evaluation system. This rating reflects the company's strong financial performance, market positioning, and growth prospects in the pharmaceutical industry. Evoke Pharma Inc's innovative products and patient-centric approach contribute to its high rating, indicating a favorable outlook for investors.

Sources and Disclaimers: Sources used for this analysis include company reports, financial statements, industry publications, and reputable financial websites. This overview is intended for informational purposes only and should not be used as the sole basis for investment decisions. Investors are advised to conduct their own research and consult with financial professionals before making investment choices.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Evoke Pharma Inc

Exchange NASDAQ Headquaters Solana Beach, CA, United States
IPO Launch date 2013-09-25 Co-Founder, CEO & Director Mr. Matthew J. D'Onofrio MBA
Sector Healthcare Website https://www.evokepharma.com
Industry Drug Manufacturers - Specialty & Generic Full time employees 4
Headquaters Solana Beach, CA, United States
Co-Founder, CEO & Director Mr. Matthew J. D'Onofrio MBA
Website https://www.evokepharma.com
Website https://www.evokepharma.com
Full time employees 4

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​